Hile Bio-Technology adjusts equity, governance after mixed Q3 earnings

Shanghai Hile Bio-Technology (SSE:603718) reported a Q3 2025 operating revenue of 39.97 million yuan, a 40.20% decrease year-over-year, primarily due to heightened market competition and product price reductions. Total profit for the period increased by 179.73% to 7.34 million yuan. For the nine months ended September 30, 2025, operating revenue was 149.74 million yuan, a 14.15% decrease from the previous year, while net profit attributable to shareholders remained stable at 20.33 million yuan, a 0.77% increase.

The company has approved the repurchase and cancellation of 3.7575 million restricted shares and 3 million stock options from its 2023 incentive plan. This adjustment follows the second restricted period's performance conditions not being met and several employee departures. The repurchase price for restricted shares is adjusted to 4.6729 yuan per share, and the exercise price for stock options to 9.4429 yuan per share, reflecting the 2024 annual dividend distribution. This will reduce Hile Bio-Technology's total share capital from 655.66 million shares to 651.90 million shares.

The company also announced a change in its accounting firm, appointing Sigma Certified Public Accountants (Special General Partnership) for the 2025 financial year, replacing Zhongxinghua Certified Public Accountants. This change, effective from 2025, aligns with the company's operational needs and audit service requirements. An extraordinary general meeting will be held on November 14, 2025, to approve this and other related matters.